Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 8/20 | 0.32 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.30 |
| ▸ | TMPRSS2 | O15393 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25826531 | 0.94 | TMPRSS2 (0.32) | PIK3CDRIPK1TMPRSS2 | |
| SCHEMBL26382838 | 0.91 | PIK3CD (0.33) | PIK3CDRIPK1TMPRSS2 | |
| SCHEMBL26382941 | 0.90 | PIK3CD (0.31) | PIK3CD | |
| SCHEMBL25826894 | 0.88 | TMPRSS2 (0.38) | PIK3CDRIPK1TMPRSS2 | |
| SCHEMBL25826889 | 0.86 | TMPRSS2 (0.37) | PIK3CDRIPK1TMPRSS2 | |
| SCHEMBL25826406 | 0.86 | — | — | |
| Remidevir SCHEMBL23959877 | 0.85 | TMPRSS2 (0.38) | PIK3CDRIPK1TMPRSS2 | |
| Remidevir SCHEMBL30996064 | 0.85 | TMPRSS2 (0.38) | PIK3CDRIPK1TMPRSS2 | |
| Remidevir SCHEMBL25366324 | 0.85 | TMPRSS2 (0.38) | PIK3CDRIPK1TMPRSS2 | |
| Remidevir SCHEMBL25365610 | 0.85 | TMPRSS2 (0.38) | RIPK1TMPRSS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230312584-A1 | SALT OF NUCLEOSIDE ANALOG, AND CRYSTAL FORM, PHARMACEUTICAL COMPOSITION AND USE THEREOF | VIGONVITA LIFE SCIENCES CO., LTD. (CN) | 2023-10-05 | — | — | US | disclosed |
| US-20230219993-A1 | ANTIVIRAL APPLICATION OF NUCLEOSIDE ANALOG OR COMBINATION FORMULATION CONTAINING NUCLEOSIDE ANALOG | VIGONVITA LIFE SCIENCES CO., LTD. (CN) | 2023-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230312584-A1 | SALT OF NUCLEOSIDE ANALOG, AND CRYSTAL FORM, PHARMACEUTICAL COMPOSITION AND USE THEREOF | PNP, SLC28A1, SLC28A2 | PIK3CD 1955/4885RIPK1 3786/4885TMPRSS2 4164/4885 |
| US-20230219993-A1 | ANTIVIRAL APPLICATION OF NUCLEOSIDE ANALOG OR COMBINATION FORMULATION CONTAINING NUCLEOSIDE ANALOG | PNP, TYMP, PIGS | PIK3CD 774/4885RIPK1 561/4885TMPRSS2 145/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.